TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Hope S Rugo, Peter Schmid, Javier Cortes...
https://pubmed.ncbi.nlm.nih.gov/42535874/Actively Recruiting
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-13
1000
Participants Needed
283
Research Sites
N/A
Total Duration
Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.
CONDITIONS
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
T
Toll Free Number
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Merck Sharp & Dohme LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Sac‑TMT | Sac‑TMT + Pembrolizumab | TPC Chemotherapy |
|---|---|---|---|
| What it is | An investigational antibody‑drug conjugate targeting TROP2, given as monotherapy | The same antibody‑drug conjugate combined with pembrolizumab | Standard chemotherapy chosen by physician (paclitaxel, nab‑paclitaxel, or gemcitabine plus carboplatin) |
| Primary use | Test whether sac‑TMT alone can improve outcomes versus physician’s choice chemotherapy | Test whether adding pembrolizumab enhances sac‑TMT results compared with chemotherapy | Provide active chemotherapy control to compare investigational treatments |
| Evidence status | Early-phase data in heavily pretreated metastatic TNBC have shown improved progression‑free survival versus chemotherapy | Combination approach is biologically plausible but lacks published efficacy results yet | Physician‑chosen chemotherapy remains standard first‑line option in PD‑L1 low metastatic TNBC |
| Important limitations | Benefit shown in prior trials was in patients who had received multiple prior therapies, not treatment‑naive metastatic TNBC | No efficacy data yet published for the combination in first‑line metastatic setting | Chemotherapy efficacy remains modest and is associated with toxicities |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Until disease progression, toxicity, or discontinuation
Participants receive sacituzumab tirumotecan alone every two weeks, sacituzumab tirumotecan plus pembrolizumab every two and six weeks respectively, or chemotherapy chosen by their physician according to the assigned group until disease progression, unacceptable side effects, or discontinuation.
Regular visits as per treatment schedule
Duration - Up to 61 months
Participants are monitored for progression-free and overall survival, response to treatment, quality of life, and adverse events for up to about 61 months.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Hope S Rugo, Peter Schmid, Javier Cortes...
https://pubmed.ncbi.nlm.nih.gov/42535874/Merck Sharp & Dohme LLC
Lead Sponsor